Med-tech financings exceeded $1 billion for the third consecutive month, reaching a total of $1.07 billion in transactions in December. In November, med-techs raised $1.02 billion, with $1.23 billion raised in October. The overall average for financings in 2023 stands at $1.47 billion per month, down from a monthly average of $3.19 billion the previous year.

Biopharmas raising money in public or private financings, including: Avistone, Beckley, Claris, Dyne, Fortress, Hibio, Inkstone Feibo, Keros, Longboard, Moonwalk, Oncusp, Resalis, Sellas.

Med-tech firms raising money in public or private financings, including: Ceretype, Nalu, Ok2Standup, Vmocion.

Remix Therapeutics Inc. has closed a $60 million financing to advance its lead program, REM-422, into the clinic and for further advancement of a pipeline of RNA processing targeted therapeutics.

Biopharmas raising money in public or private financings, including: Arrowhead, CG Oncology, Crinetics, Enyo, Journey Medical, Longboard, Radionetics, Remix, Vasa.

Med-tech firms raising money in public or private financings, including: Bluejay Diagnostics, Cardiomech, Meihua International Medical Technologies, Radionetics.

Biopharmas raising money in public or private financings, including: Aditxt, Akari, Apollo, Betterlife, Graviton, Immunitybio, Mannkind, Verona.

Biopharmas raising money in public or private financings, including: Fortress, Scinai, Trevena.

Med-tech firms raising money in public or private financings, including: Inspira, Microbot, Neurolief.